Literature DB >> 19320529

Management of patients presenting with acute psychotic episodes of schizophrenia.

Pierre Thomas1, Köksal Alptekin, Mihai Gheorghe, Mauro Mauri, José Manuel Olivares, Michael Riedel.   

Abstract

The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320529     DOI: 10.2165/00023210-200923030-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  128 in total

1.  A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.

Authors:  J-M Vanelle; S Douki
Journal:  Eur Psychiatry       Date:  2006-11-20       Impact factor: 5.361

Review 2.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.

Authors:  Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2005       Impact factor: 4.132

Review 3.  EPS profiles: the atypical antipsychotics are not all the same.

Authors:  Peter J Weiden
Journal:  J Psychiatr Pract       Date:  2007-01       Impact factor: 1.325

4.  Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial.

Authors:  L Fialko; D Freeman; P E Bebbington; E Kuipers; P A Garety; G Dunn; D Fowler
Journal:  Acta Psychiatr Scand       Date:  2006-09       Impact factor: 6.392

5.  Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.

Authors:  Elizabeth B Stuyt; Terrie A Sajbel; Michael H Allen
Journal:  Am J Addict       Date:  2006 Mar-Apr

6.  Osteoporosis in patients with schizophrenia.

Authors:  Martina Hummer; Peter Malik; Rudolf W Gasser; Alex Hofer; Georg Kemmler; Roy Cesar Moncayo Naveda; Maria A Rettenbacher; W Wolfgang Fleischhacker
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

7.  Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

Authors:  Veronica O'Keane; Anna Maria Meaney
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

Review 8.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09

10.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  12 in total

Review 1.  [Acute agitation conditions].

Authors:  P Mavrogiorgou; G Juckel
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

2.  Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.

Authors:  Sarah Baltzley; Atiquzzaman Mohammad; Ahmad H Malkawi; Abeer M Al-Ghananeem
Journal:  AAPS PharmSciTech       Date:  2014-08-21       Impact factor: 3.246

Review 3.  Nonaffective acute psychoses: uncertainties on the way to DSM-V and ICD-11.

Authors:  Katie L Nugent; Diana Paksarian; Ramin Mojtabai
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

Review 4.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

Review 5.  Aripiprazole: a review of its use in the management of schizophrenia in adults.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 6.  The management of psychiatric emergencies.

Authors:  Paraskevi Mavrogiorgou; Martin Brüne; Georg Juckel
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

7.  Antipsychotic agents: efficacy and safety in schizophrenia.

Authors:  Arão Nogueira de Araújo; Eduardo Pondé de Sena; Irismar Reis de Oliveira; Mario F Juruena
Journal:  Drug Healthc Patient Saf       Date:  2012-11-29

8.  Patient perspectives on antipsychotic treatments and their association with clinical outcomes.

Authors:  Hong Liu-Seifert; Olawale O Osuntokun; Jenna L Godfrey; Peter D Feldman
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

9.  Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup.

Authors:  Kimberly Nordstrom; Leslie S Zun; Michael P Wilson; Victor Stiebel; Anthony T Ng; Benjamin Bregman; Eric L Anderson
Journal:  West J Emerg Med       Date:  2012-02

10.  A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Authors:  Hideaki Katagiri; Shinji Fujikoshi; Takuya Suzuki; Kiyoshi Fujita; Naoya Sugiyama; Michihiro Takahashi; Juan-Carlos Gomez
Journal:  BMC Psychiatry       Date:  2013-01-11       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.